Ergomed has entered into a co-development agreement with Allergy Therapeutics for three of its OralVac products. The first Phase I trial (in house dust mites) will commence in 2018. Ergomed will contribute in-kind to the development of the products and will receive service fees as well as royalties on net sales. Ergomed has extensive experience in the allergy field and we view it as a good fit for the group’s co-development pipeline. We continue to favour Ergomed’s integrated business model and ....
12 Dec 2017
N+1 Singer - Ergomed - Co-development agreement with Allergy Therapeutics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - Co-development agreement with Allergy Therapeutics
- Published:
12 Dec 2017 -
Author:
Sheena Berry -
Pages:
3
Ergomed has entered into a co-development agreement with Allergy Therapeutics for three of its OralVac products. The first Phase I trial (in house dust mites) will commence in 2018. Ergomed will contribute in-kind to the development of the products and will receive service fees as well as royalties on net sales. Ergomed has extensive experience in the allergy field and we view it as a good fit for the group’s co-development pipeline. We continue to favour Ergomed’s integrated business model and ....